PrEP - pre-exposure prophylaxis
Jun 17, 2021 | Stories from the Field
Through the loss of her mother, husband, and two children over a nine-year period, ICAP’s Enala Daudi discovered her purpose as a community health worker—using her lived experiences to accompany her clients throughout their own health journeys after a new HIV...
Jul 7, 2020 | News
Researchers from the HIV Prevention Trials Network (HPTN) announced today that the HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every eight weeks was superior to daily oral...
May 19, 2020 | In the Media, News
The HIV Prevention Trials Network (HPTN) announced results from HPTN 083, a global randomized, controlled, double-blind study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC)...
Mar 24, 2020 | News
Two ICAP videos won honors in the 7th Annual CUGH-Pulitzer Global Health Video Competition, held by the Colleges and Universities in Global Health (CUGH). First place in the High Impact Programs Category went to the Population-based HIV Impact Assessment (PHIA)...
Feb 24, 2020 | News
As part of a combination prevention package, PrEP (or pre-exposure prophylaxis) is proving to be a key intervention to stemming the tide of new HIV infections, particularly those most at-risk for contracting the virus including people who inject drugs, men who have...
